DJIA 17,098.45 0.00 0.00%
NASDAQ 4,580.27 0.00 0.00%
S&P 500 2,003.37 0.00 0.00%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Nektar 181 Could Dominate A $13B Chronic Pain Market

Monday's ETF Movers: FBT, GDX

Positive Data on Baxter's Trial for BAX 855 - Analyst Blog

Positive Data on Baxter's Trial for BAX 855 - Analyst Blog

Nektar Therapeutics Has More To Give

Nektar Therapeutics Harnesses The Power Of AstraZeneca To Move Movantik

Nektar President Howard Robin Is Listening To You

Nektar's Loss Narrows in Q2, Beats Revenues, Retains View - Analyst Blog

Nektar's Loss Narrows in Q2, Beats Revenues, Retains View - Analyst Blog

Nektar Therapeutics' (NKTR) CEO Howard Robin on Q2 2014 Results - Earnings Call Transcript

Nektar: Reason Will Rarely Fail You

Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Re

Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
See More Articles...